Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder of unknown cause. It is characterized by follicular hyperkeratosis, scaly erythematous plaques, palmoplantar keratoderma, and frequent progression to generalized erythroderma.1 Six types of PRP are distinguished, with type 1 being the most common form in adults. Disease management of PRP is challenging for lack of specific guidelines. Topical emollients, corticosteroids, and salicylic acid alone or combined with systemic retinoids, methotrexate, and tumor necrosis factor (TNF) inhibitors are considered to be most helpful.2,3 Unfortunately, PRP often resists conventional treatment. We report the case of a 67-year-old man with refractory PRP who was successfully treated with secukinumab.
Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol. 2016;152(11):1278-1279. doi:10.1001/jamadermatol.2016.3885